Advancements in the Management of Gynecological Cancers: ESMO 2024 - Episode 13

Innovative Combination Strategies for Endometrial Cancer: Updates from LEAP and KEYNOTE-B21 Trials

November 11, 2024

Angeles Alvarez Secord, MD, MHSc , Dana M. Chase, MD, FACOG, Bhavana Pothuri, MD, Premal H. Thaker, MD, MS, Thomas C. Krivak, MD

Panelists discuss emerging data from ongoing trials evaluating innovative combination strategies for endometrial cancer, including insights from the LEAP trial (pembrolizumab + lenvatinib) and the KEYNOTE-B21 trial (pembrolizumab + chemotherapy with or without radiotherapy). They also address treatment considerations for patients with sentinel lymph node–positive disease.

EP. 1: Approaching Biomarker Testing and Frontline Maintenance Therapy for Advanced Ovarian Cancer

EP. 2: Key Findings from the PRIMA Trial: Niraparib in 1L Maintenance for Advanced Ovarian Cancer

EP. 3: Duration of PARP Inhibitor Maintenance Therapy for Ovarian Cancer

EP. 4: Emerging Combinations in Maintenance Therapy for Ovarian Cancer

EP. 5: Optimizing Ovarian Cancer Care: PARP Resistance, Management of Oligoprogression, and Adverse Event Mitigation

EP. 6: Use of Trastuzumab Deruxtecan in Ovarian Cancer

EP. 7: Antibody-Drug Conjugates in Ovarian Cancer: Emerging Data and Treatment Integration

EP. 8: Navigating Treatment Strategies for Advanced Cervical Cancer: Localized Therapy, KEYNOTE-A18 Trial Data, and Frontline Approaches

EP. 9: Integrating Tisotumab Vedotin into Ovarian Cancer Therapy

EP. 10: Biomarker Testing in Advanced Endometrial Cancer: Approach, Key Markers, and Impact on Treatment Decisions

EP. 11: Managing Recurrent Endometrial Cancer: Treatment Strategies and RUBY Trial Insights

EP. 12: Durvalumab in Endometrial Cancer: DUO-E Trial Updates